Publications by authors named "Agnieszka Konska"
Mass spectrometry (MS) can detect multiple myeloma-derived monoclonal proteins in the peripheral blood (PB) with high sensitivity, potentially serving as a PB assay for measurable residual disease (MRD). This study evaluated the significance of PB MS MRD negativity during posttransplant therapy in patients with newly diagnosed multiple myeloma. Serum samples from 138 patients treated in the phase 3 ATLAS trial of posttransplant maintenance with either carfilzomib, lenalidomide, and dexamethasone, or with lenalidomide alone were analyzed using EXENT MS methodology.
View Article and Find Full Text PDFBackground: Lenalidomide is a cornerstone of maintenance therapy in patients with newly diagnosed multiple myeloma after autologous stem-cell transplantation. We aimed to compare the efficacy and safety of maintenance therapy with carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone in this patient population.
Methods: This study is an interim analysis of ATLAS, which is an investigator-initiated, multicentre, open-label, randomised, phase 3 trial in 12 academic and clinical centres in the USA and Poland.
Background: The first-line obinutuzumab-based immunochemotherapy improves the outcome of patients with follicular lymphoma (FL) compared with rituximab-based regimens. However, infusion-related reactions occur in almost half of patients during the 1st obinutuzumab administration.
Objectives: The study aimed to evaluate the early effectiveness and safety of obinutuzumab-based induction regimens in a real-world setting.
Article Synopsis
- Follicular lymphoma (FL) is a common, low-grade B-cell lymphoma typically treated with rituximab and chemotherapy, with recent advancements in treatment options.
- A study of 181 newly diagnosed FL patients revealed that 77% had advanced disease at diagnosis, and the median progression-free survival was 8.28 years, with some patients experiencing transformation to aggressive lymphoma.
- Key factors for better survival rates included having a good performance status (ECOG 0), low PRIMA prediction index, and not relapsing within 24 months of treatment.
Background: The standard first-line treatment for primary mediastinal B-cell lymphoma (PMBCL) patients is rituximab-based immunochemotherapy; however, this is not due to the result of randomized clinical trials.
Aims: We retrospectively investigated 53 PMBCL patient outcomes treated either with R-CHOP-21 or DA-EPOCH-R-28. The primary endpoint was overall survival (OS).